Tuesday, 8 May 2018

GDUFA (Generic Drugs User free Amendment)


 GDUFA (Generic Drugs User free Amendment)




The Generic Drug User Fee Amendments of 2012 authorizes FDA to assess and collect user fees for human generic drug applications, certain application supplements, and related manufacturers. Form FDA 3794, also known as the Generic Drug User Fee Cover Sheet or GDUFA Cover Sheet, is designed to collect the minimum necessary information to determine the total applicable user fee required and to help FDA track the user fee payments. Furthermore, FDA’s review of a generic drug submission cannot begin until all relevant user fee obligations have been satisfied.

GDUFA is applicable for following cases

  • Abbreviated new drug application (ANDA) or applicable amendment;
  • Prior approval supplement (PAS) or applicable amendment;
  • Type II active pharmaceutical ingredient (API) drug master file (DMF) that is referenced on or after October 1, 2012, in a generic drug submission to the FDA and for which the DMF fee has not already been paid;
  • Generic drug facility which is identified in at least one generic drug submission that is approved to produce a finished dosage form (FDF) of a human generic drug or an API contained in a human generic drug; and
  • Backlog ANDA which is pending on October 1, 2012, and that has not received a tentative approval prior to that date.


Serialisation and tractability in pharmaceuticals



 Serialisation and tractability in pharmaceuticals


Pharmaceutical serialisation is the tracking and tracing of the passage of prescription drugs through the supply chain from manufacturing to dispensing.By implementing serialisation counterfeiting in pharmaceuticals can be reduced. 

Serialisation could potentially identify every product by a unique serial number (in the form of a two-dimensional code known as a data matrix) in addition to the origin,shelf life and batch number for that product. This could potentially allow the products life cycle to be traced from production,through distribution and finally to the patient. 



COMPUTER VALIDATION RELATED GUIDELINES IN PHARMACEUTICALS






Computer Validation Related Guidelines In Pharmaceuticals



EU GMP Annex 11: Computerised Systems
FDA Guidance for Industry: Part 11, Electronic Records, Electronic Signatures: Scope and Application
FDA Guidance for Industry; Blood Establishment Computer Systems Validation in the User's Facility
PIC/S Good Practices for Computerised Systems in Regulated "GXP" Environments (PI 011-3) Sept 2007
APIC - Computer validation Guide, December 2002
FDA Guide to Inspections of Computerised Systems in Drug Processing, February 1983
FDA Glossary of Computerized System and Software Development Terminology
Guideline on Management of Computerized Systems for Marketing Authorization Holders and Manufacturers of Drugs and Quasi-drugs
Computerized systems used in clinical trials
FDA Guidance for Industry: Computerized Systems used in clinical trials-Draft
APIC - Technical Change Control Guideline 2004 (October 2004)
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations
“Computer Crossmatch” (Computerized Analysis of the Compatibility between the Donor’s Cell Type and the Recipient’s Serum or Plasma Type)
FDA Guidance for Industry Blood Establishment Computer System Validation in the User’s Facility Draft Guidance
Eudralex Volume 10 Annex III To Guidance For The Conduct Of Good Clinical Practice Inspections Computer Systems
Eudralex Volume 10 Annex V Guidance For the Conduct Of Good Clinical Practice Inspections: Phase I Units
FDA Compliance Policy Guide Sec. 425.100 Computerized Drug Processing; CGMP Applicability to Hardware and Software (CPG 7132a.17)
FDA Compliance Policy Guide Sec. 425.200 Computerized Drug Processing; Vendor Responsibility (CPG 7132a.12)
FDA Compliance Policy Guide Sec. 425.300 Computerized Drug Processing; Source Code for Process Control Application Programs (CPG 7132a.15)
FDA Compliance Policy Guide Sec. 425.400 Computerized Drug Processing; Input/Output Checking (CPG 7132a.07)
FDA Compliance Policy Guide Sec. 425.500 Computerized Drug Processing; Identification of "Persons" on Batch Production and Control Records (CPG 7132a.08)
FDA Guidance for Industry Blood Establishment Computer System Validation in the User’s Facility